Venovenous Extracorporeal Membrane Oxygenation in Diffuse Alveolar Hemorrhage Secondary to Anti-neutrophil Cytoplasmic Autoantibody-associated Vasculitis : Starting without Systemic Anticoagulation
Regarding extracorporeal membrane oxygenation (ECMO) support against hemorrhagic conditions, there seems to be a dilemma when deciding between maintaining the circuit patency by systemic anticoagulation and increasing the risk of bleeding. We herein report two cases of diffuse alveolar hemorrhage (DAH) caused by myeloperoxidase (MPO) anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV) successfully treated with venovenous (VV)-ECMO support, both initially started without systemic anticoagulation. Under anticoagulation-free ECMO management, we should consider the shortcomings of frequent circuit exchange and hemorrhagic diathesis related to circuit-induced disseminated intravascular coagulation (DIC).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Internal medicine (Tokyo, Japan) - 61(2022), 23 vom: 01. Dez., Seite 3569-3573 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ohta, Soichi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoantibodies |
|---|
| Anmerkungen: |
Date Completed 02.12.2022 Date Revised 06.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2169/internalmedicine.9472-22 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340928719 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340928719 | ||
| 003 | DE-627 | ||
| 005 | 20231226010608.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2169/internalmedicine.9472-22 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1136.xml |
| 035 | |a (DE-627)NLM340928719 | ||
| 035 | |a (NLM)35569985 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ohta, Soichi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Venovenous Extracorporeal Membrane Oxygenation in Diffuse Alveolar Hemorrhage Secondary to Anti-neutrophil Cytoplasmic Autoantibody-associated Vasculitis |b Starting without Systemic Anticoagulation |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.12.2022 | ||
| 500 | |a Date Revised 06.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Regarding extracorporeal membrane oxygenation (ECMO) support against hemorrhagic conditions, there seems to be a dilemma when deciding between maintaining the circuit patency by systemic anticoagulation and increasing the risk of bleeding. We herein report two cases of diffuse alveolar hemorrhage (DAH) caused by myeloperoxidase (MPO) anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV) successfully treated with venovenous (VV)-ECMO support, both initially started without systemic anticoagulation. Under anticoagulation-free ECMO management, we should consider the shortcomings of frequent circuit exchange and hemorrhagic diathesis related to circuit-induced disseminated intravascular coagulation (DIC) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a diffuse alveolar hemorrhage | |
| 650 | 4 | |a extracorporeal membrane oxygenation | |
| 650 | 4 | |a myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated vasculitis | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 700 | 1 | |a Matsuyoshi, Takeo |e verfasserin |4 aut | |
| 700 | 1 | |a Kaneko, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kosen, Daiyu |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Hamaguchi, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Yuichi |e verfasserin |4 aut | |
| 700 | 1 | |a Shimizu, Keiki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine (Tokyo, Japan) |d 1996 |g 61(2022), 23 vom: 01. Dez., Seite 3569-3573 |w (DE-627)NLM012606731 |x 1349-7235 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2022 |g number:23 |g day:01 |g month:12 |g pages:3569-3573 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2169/internalmedicine.9472-22 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2022 |e 23 |b 01 |c 12 |h 3569-3573 | ||